Quest Diagnostics Incorporated (DGX) exhibits 33.2% gross margins and 10.3% return on invested capital within Health Care (Medical Specialities), balanced against a 16.3x enterprise multiple and 6.9% implied options volatility.
Sustained 33.2% gross profitability converts into 14.1% operating margin and 10.3% ROIC, outpacing sector cost of capital.
ROIC: 10.3% // GM: 33.2%YoY revenue trajectory of +11.8% paired with 4.88% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +11.8% // FCF YLD: 4.88%Altman Z-Score of 4.01 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.01 // F-SCORE: 8/9Trading at 28.1x trailing P/E (26.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 28.1x // EV/EBITDA: 16.3xOptions market prices a ±6.9% implied move with a 0.78 put/call ratio around $248.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.78Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend 9.0% net margins.
NET MARGIN: 9.0% // D/E: 0.72x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for DGX & activate live FRED threshold breach alerts.